YK Bioventures

YK Bioventures

YK Bioventures launched in 2020 with a clear premise: that translational science demands translational capital. Founded by Michael Chen and Timothy Lu, the firm emerged from the intersection of deep academic research and venture formation. Both principals maintain active faculty positions — Lu at MIT in biological engineering, Chen at Stanford in bioengineering — creating a sourcing pipeline that runs directly through university labs. The firm operates from a distributed office network spanning Palo Alto, Cambridge, New Haven, and Beijing, reflecting both the geographies of biotech innovation and the founders' institutional ties. The firm targets pre-seed and seed-stage companies where scientific risk remains high but the distance to clinical application is shortening. Its portfolio clusters around three domains: therapeutics enabled by synthetic biology, AI-driven drug discovery platforms, and digital health infrastructure. Confirmed positions include Senti Biosciences, a cell therapy company that went public via SPAC in 2022, and Amber Bio, a gene-editing startup backed alongside Andreessen Horowitz and Pillar VC. YK Bioventures participates primarily in equity rounds, typically leading or co-leading seed financings with check sizes ranging between $500,000 and $2 million. The firm also makes select follow-on investments through Series A and B rounds when syndicate dynamics allow. Geographic exposure is concentrated in the Boston-Cambridge and San Francisco Bay Area corridors, with additional exposure to Greater China through its Beijing office. The firm's organizational model is deliberately lean — structured as a partnership without a large analyst class or institutional fundraising apparatus. Its capital base is anchored by the founders and a network of high-net-worth individuals from the biotechnology and technology sectors. No separate philanthropic foundation or adjacent vehicle has been disclosed, though the firm's principals are active in academic grants and translational research programs at their respective institutions. In 2023, the firm added a Beijing presence to support portfolio companies pursuing China-based clinical trials and manufacturing partnerships (public record). What distinguishes YK Bioventures from other seed-stage biotech funds is its embedded academic sourcing model. The firm does not rely on inbound pitch decks or accelerator demo days — its deal flow originates inside the laboratories where the science is being invented. Chen and Lu actively publish and peer-review in synthetic biology and CRISPR-related fields, giving them early visibility into discoveries months before they reach traditional venture networks. This architecture makes the firm function less like a conventional fund and more like a technology-transfer extension for the labs it works with, compressing the timeline between publication and company formation.